Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 16/20 | 0.50 |
| ▸ | HTR2C | P28335 | 15/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.45 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3469273 | 0.84 | HTR2A (0.54) | HTR2AHTR2CUSP2HPGDHSD17B10 | |
| SCHEMBL4040584 | 0.73 | GAA (0.64) | POLBGAA | |
| SCHEMBL2743214 | 0.70 | HTR2A (0.55) | HTR2AHTR2CL3MBTL1ALDH1A1GAA | |
| SCHEMBL4260839 | 0.69 | GAA (0.60) | HTR2AHTR2CALDH1A1GAA | |
| SCHEMBL8230948 | 0.68 | HDAC1 (0.54) | ALDH1A1GAA | |
| SCHEMBL2427453 | 0.68 | HDAC3 (0.57) | HSD17B10ALDH1A1LMNA | |
| SCHEMBL14487965 | 0.67 | LTA4H (0.54) | HTR2AALDH1A1 | |
| SCHEMBL21077844 | 0.67 | MCHR1 (0.58) | HTR2AHTR2CLMNA | |
| SCHEMBL1272763 | 0.66 | PLA2G10 (0.50) | HSD17B10L3MBTL1ALDH1A1POLB | |
| SCHEMBL2906006 | 0.66 | HDAC6 (0.68) | LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | HTR2A 3250/4885HTR2C 2716/4885USP2 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.